Farhad Ravandi

460 total citations
17 papers, 196 citations indexed

About

Farhad Ravandi is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Farhad Ravandi has authored 17 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 7 papers in Genetics and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Farhad Ravandi's work include Acute Myeloid Leukemia Research (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Farhad Ravandi is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Farhad Ravandi collaborates with scholars based in United States, Netherlands and Switzerland. Farhad Ravandi's co-authors include H. Kantarjian, Alan K. Burnett, Elihu H. Estey, Gert J. Ossenkoppele, Robert K. Hills, Anna Evans, Marie‐Christiane Vekemans, Roland B. Walter, Sherry R. Pierce and Thomas Pabst and has published in prestigious journals such as Blood, Cancer and British Journal of Haematology.

In The Last Decade

Farhad Ravandi

11 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farhad Ravandi United States 4 167 77 63 44 34 17 196
Claudia Venturi Italy 8 175 1.0× 61 0.8× 89 1.4× 92 2.1× 56 1.6× 23 234
Maria Chiara Abbenante Italy 7 83 0.5× 80 1.0× 45 0.7× 66 1.5× 45 1.3× 27 173
Desiree De Lange Netherlands 3 147 0.9× 67 0.9× 40 0.6× 78 1.8× 15 0.4× 5 190
Rabia Shahswar Germany 6 157 0.9× 68 0.9× 120 1.9× 22 0.5× 15 0.4× 12 185
Lene Hyldahl Ebbesen Denmark 8 152 0.9× 100 1.3× 77 1.2× 19 0.4× 24 0.7× 13 215
Erika Morsia Italy 6 136 0.8× 67 0.9× 71 1.1× 18 0.4× 32 0.9× 26 169
Micaela Bergamaschi Italy 7 79 0.5× 61 0.8× 38 0.6× 24 0.5× 16 0.5× 11 131
Eveline S. de Bont Netherlands 5 72 0.4× 36 0.5× 47 0.7× 28 0.6× 15 0.4× 16 117
Daniela Žáčková Czechia 8 140 0.8× 25 0.3× 109 1.7× 14 0.3× 40 1.2× 34 175
Laure Morisset France 4 70 0.4× 42 0.5× 39 0.6× 16 0.4× 34 1.0× 5 119

Countries citing papers authored by Farhad Ravandi

Since Specialization
Citations

This map shows the geographic impact of Farhad Ravandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Ravandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Ravandi more than expected).

Fields of papers citing papers by Farhad Ravandi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farhad Ravandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Ravandi. The network helps show where Farhad Ravandi may publish in the future.

Co-authorship network of co-authors of Farhad Ravandi

This figure shows the co-authorship network connecting the top 25 collaborators of Farhad Ravandi. A scholar is included among the top collaborators of Farhad Ravandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farhad Ravandi. Farhad Ravandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2025). A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia. HemaSphere. 9(10). e70214–e70214.
2.
Sasaki, Koji, Peter H. Wiernik, Tapan M. Kadia, et al.. (2025). Mortality and relapse dynamics in AML after three years of complete remission. Leukemia & lymphoma. 66(13). 2498–2503.
3.
Short, Nicholas J., Tapan M. Kadia, Naveen Pemmaraju, et al.. (2025). A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 25(11). 800–807.
4.
Kantarjian, Hagop M., Gautam Borthakur, Naval Daver, et al.. (2025). A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens. Cancer. 131(21). e70113–e70113.
5.
Montalban‐Bravo, Guillermo, Farhad Ravandi, Nicholas J. Short, et al.. (2025). Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research. 153. 107692–107692. 1 indexed citations
6.
Bataller, Álex, Bofei Wang, Courtney D. DiNardo, et al.. (2025). Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leukemia & lymphoma. 66(7). 1221–1233.
7.
Bazinet, Alexandre, Álex Bataller, Tapan M. Kadia, et al.. (2025). A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia. Cancer. 131(6). e35813–e35813. 3 indexed citations
8.
Garcia‐Manero, Guillermo, Tapan M. Kadia, Naval Daver, et al.. (2025). A case series of oral decitabine–cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. Leukemia & lymphoma. 66(9). 1727–1730.
9.
Haddad, Fadi, Hagop M. Kantarjian, Nicholas J. Short, et al.. (2025). Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy. Journal of the National Comprehensive Cancer Network. 23(8). 1 indexed citations
10.
Short, Nicholas J., Nitin Jain, Jayastu Senapati, et al.. (2024). ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24. S284–S285. 6 indexed citations
11.
12.
13.
Kantarjian, Hagop M., Koji Sasaki, Nicholas J. Short, et al.. (2024). Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML. Blood. 144(Supplement 1). 2853–2853. 1 indexed citations
14.
Ravandi, Farhad, et al.. (2022). P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. HemaSphere. 6. 267–268. 1 indexed citations
15.
Cripe, Larry D., Glenn Michelson, Judith A. Fox, et al.. (2014). A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 100(2). 231–237. 24 indexed citations
16.
Walter, Roland B., Megan Othus, Alan K. Burnett, et al.. (2014). Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 29(2). 312–320. 116 indexed citations
17.
Ravandi, Farhad, Jörge E. Cortes, Maher Albitar, et al.. (1999). Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance. British Journal of Haematology. 107(3). 581–586. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Venturi Breakdown of academic impact, for papers by Maria Chiara Abbenante Breakdown of academic impact, for papers by Desiree De Lange Breakdown of academic impact, for papers by Rabia Shahswar Breakdown of academic impact, for papers by Lene Hyldahl Ebbesen Breakdown of academic impact, for papers by Erika Morsia Breakdown of academic impact, for papers by Micaela Bergamaschi Breakdown of academic impact, for papers by Eveline S. de Bont Breakdown of academic impact, for papers by Daniela Žáčková Breakdown of academic impact, for papers by Laure Morisset
Rankless by CCL
2026